BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is a major type of liver cancer associated with high mortality. Prognosis is poor in HCC patients largely because of late diagnosis and limitations in treatment options. Therefore, this study aims to identify alternative target for HCC in hope to offer new treatments to patients. Cadherin-17 (CDH17) has been identified as an oncofetal molecule of HCC and that a suppression of its expression by RNA interference (RNAi) leads to anti-tumorigenesis. To supplement the drawbacks associated with the use of RNAi approach in biotherapy, we developed specific antibody against CDH17 for achieving similar purpose. METHODS: Hybridoma cell clones capable of secreting antibodies ...

Description

This journal suppl. entitled: Abstracts of The International Liver Congress™ 2012 – 47th annual meeting of the European Association for the Study of the Liver / Poster Abstracts

This journal suppl. entitled: Abstracts of The International Liver Congress™ 2012 – 47th annual meeting of the European Association for the Study of the Liver / Poster Abstracts

-

dc.description.abstract

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is a major type of liver cancer associated with high mortality. Prognosis is poor in HCC patients largely because of late diagnosis and limitations in treatment options. Therefore, this study aims to identify alternative target for HCC in hope to offer new treatments to patients. Cadherin-17 (CDH17) has been identified as an oncofetal molecule of HCC and that a suppression of its expression by RNA interference (RNAi) leads to anti-tumorigenesis. To supplement the drawbacks associated with the use of RNAi approach in biotherapy, we developed specific antibody against CDH17 for achieving similar purpose. METHODS: Hybridoma cell clones capable of secreting antibodies ...

-

dc.language

eng

-

dc.publisher

Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep

-

dc.relation.ispartof

Journal of Hepatology

-

dc.rights

NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Hepatology, v. 56, suppl. 2 (April 2012). DOI: 10.1016/S0168-8278(12)60300-6

-

dc.rights

Creative Commons: Attribution 3.0 Hong Kong License

-

dc.subject

Medical sciences

-

dc.subject

Gastroenterology

-

dc.title

Monoclonal antibody against cadherin-17 as a potential treatment for liver cancer